Mechanisms of formation and progression of cardiovascular pathology in obesity

Obesity is currently recognized as a pandemic of modernity and a serious medical and social problem that brings significant economic damage to society. This is largely due to the increase and younger onset of obesity-related morbidity, accompanied by cardiovascular pathology, which worsens quality of life, leading to early temporary and permanent loss of working capacity and premature death. This review presents an analysis of current understanding of the risks and mechanisms of cardiovascular system damage in obesity, the role of insulin resistance, the hormonal activity of adipose tissue, and the prognostic significance of different types of obesity. Along with traditional cardiovascular risk factors, obesity is associated with a range of metabolic and hormonal disorders, the development of systemic inflammation, and oxidative stress, leading to specific myocardial damage—lipotoxic cardiomyopathy. This pathological condition significantly contributes to the development of myocardial dysfunction (heart failure, urgent arrhythmias with the risk of sudden cardiac death) even in the absence of ischemic heart disease. The review provides current data on the features of myocardial remodeling in obesity, the mechanisms of its development and progression, and methods of diagnosis. It emphasizes that the problem of diagnosing myocardial dysfunction, as well as adequate treatment of this pathology—including non-drug interventions, surgical procedures, and the use of weightloss medications—is far from being resolved. This necessitates in-depth research into this pathology and the search for new, optimal, effective, and safe methods for prevention and treatment.

1. Alferova V.I., Mustafina S.V. The prevalence of obesity in the adult population of the Russian Federation (literature review). Obesity and metabolism. 2022;19(1):96–105. (In Russian). DOI: 10.14341/omet12809

2. Raeisi T., Mozaffari H., Sepehri N. et al. The negative impact of obesity on the occurrence and prognosis of the 2019 novel coronavirus (COVID-19) disease: a systematic review and metaanalysis. Eat. Weight Disord. 2022;27(3):893–911. DOI: 10.1007/s40519-021-01269-3

3. Healthcare in Russia. 2023: Statistical collection. Rosstat. M: Z-46; 2023:179. (In Russian). [Electronic resource]. URL: rosstat.gov.ru/storage/mediabank/Zdravoohran-2023.pdf

4. Kontsevaya A., Shalnova S., Deev A., J., Jewell J., Rakovac I. et al. Overweight and Obesity in the Russian Population: Prevalence in Adults and Association with Socioeconomic Parameters and Cardiovascular Risk Factors. Obes. Facts. 2019;12(1):103–14. DOI: 10.1159/000493885

5. Drapkina O.M., Eliashevich S.O., Shepel R.N. Obesity as a risk factor for chronic non-communicable diseases. Russ. J. Cardiol. 2016;(6):73–9. (In Russian). DOI: 10.15829/1560-4071-2016-6-73-79

6. Dedov I.I., Shestakova M.V., Galstyan G.R. Prevalence of type 2 diabetes mellitus in the adult population of Russia (NATION study). Diabetes mellitus. 2016;19(2):104–12. (In Russian). DOI: 10.14341/DM2004116-17

7. Kontsevaya A.V., Shalnova S.A., Drapkina O.M. ESSE-RF study: epidemiology and public health promotion. Cardiovascular therapy and prevention. 2021;20(5):2987. (In Russian). DOI: 10.15829/1728-8800-2021-2987

8. Oganov R.G., Maslennikova G.Ya. Demographic trends in the Russian Federation: the impact of cardiovascular disease. Cardiovascular therapy and prevention. 2012;11(1):5–10. (In Russian). DOI: 10.15829/1728-8800-2012-1-5-10

9. Lubrano C., Saponara M., Barbaro G. et al. Relationships between body fat distribution, epicardial fat and obstructive sleep apnea in obese patients with and without metabolic syndrome. PLoS One. 2012;7(10):e47059. DOI: 10.1371/journal.pone.0047059.

10. Whaley-Connell, A., Sowers J. Indices of obesity and cardiometabolic risk. Hypertension. 2011;58(6):91–3. DOI: 10.1161/HYPERTENSIONAHA.111.180406

11. Drapkina O.M., Kontsevaya A.V., Kalinina A.M., Avdeev S.M., Agaltsov M.V., Alexandrova L.M. et al. Prevention of chronic non-communicable diseases in the Russian Federation. National guidelines 2022. Cardiovascular therapy and prevention. 2022;21(4):3235. (In Russian). DOI: 10.15829/1728-8800-2022-3235

12. Usacheva E.V., Nelidova A.V., Kulikova O.M., Flyanku I.P. Mortality of Russian able-bodied population from cardiovascular diseases. Hygiene and sanitation. 2021;100(2):159–165. (In Russian). DOI: 10.47470/0016-9900-2021-100-2-159-165

13. Goldberg, I.J., Trent, C.M., Schulze, P.C. Lipid metabolism and toxicity in the. Cell metabolism. 2012;15(6):805–812. DOI: 10.1016/j.cmet.2012.04.006

14. Mozaffarian D., Benjamin E.J., Go A.S., Arnett D.K. et al. Heart disease and stroke statistics — 2015 update: a report from the American Heart Association. Circulation. 2015;131(4):e29–e322. DOI:10.1161/CIR.0000000000000152

15. Li Chuanbao, Liu Huiruo, Xu Feng, Chen Yuguo. The role of lipotoxicity in cardiovascular disease. Emergency and Critical Care Medicine. 2022; 2(4):214–218. DOI: 10.1097/EC9.0000000000000024

16. Pinto Y.M., Elliott P.M., Arbustini E., Adler Y., Anastasakis A., Böhm M., Denis Duboc D. et al. Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: aposition statement of the ESC working group on myocardial and pericardial diseases. European Heart Journal. 2016;37(23):1850–1858. DOI: 10.1093/eurheartj/ehv727

17. Bozkurt B., Colvin M., Cook J., Cooper L., Deswal A., Fonarow G., Francis G., Lenihan D. et al. Current diagnostic and treatment strategies for specific dilated cardiomyopathies: a scientific statement from the American Heart Association. Circulation. 2016;134:e579– e646. DOI: 10.1161/CIR.0000000000000455

18. Zhang Y., Jun Ren . Role of cardiac steatosis and lipotoxicity in obesity cardiomyopathy. Hypertension. 2011;57(2):148–150. DOI:10.1161/HYPERTENSIONAHA.110.164178

19. Nishida K., Kinya Otsu. Inflammation and metabolic cardiomyopathy. Cardiovasc. Res. 2017;113(4):389–398. DOI: 10.1093/cvr/cvx012

20. Drosatos K., Schulze P. Cardiac Lipotoxicity: Molecular Pathways and Therapeutic Implications. Curr. Heart Fail. Rep. 2013;10(2):109– 121. DOI: 10.1007/s11897-013-0133-0

21. Čolak E., Pap D. The Role of Oxidative Stress in the Development of Obesity and Obesity-Related Metabolic Disorders. J. Med. Biochem. 2021,40,1–9. DOI: 10.5937/jomb0-24652

22. Haffar T., Bérubé-Simard F., Bousette N. Impaired fatty acid oxidation as a cause for lipotoxicity in cardiomyocytes. Biochem. Biophys. Res. Commun. 2015;468(1–2):73–78. DOI: 10.1016/j.bbrc.2015.10.162

23. Shu H., Peng Y., Hang W., Li N., Zhou N., Wang D.W.. Emerging Roles of Ceramide in Cardiovascular Diseases. Aging Dis. 2022;13(1):232–245. DOI: 10.14336/AD.2021.0710

24. Wang X., Pu H., Ma C., Jiang T., Wei Q., Zhang C., et al. Adiponectin abates atherosclerosis by reducing oxidative stress. Med. Sci. Monit. 2014;2(20):1792–800. DOI: 10.12659/MSM.892299

25. Masenga S.K., Kabwe L.S., Chakulya M., Kirabo A. Mechanisms of Oxidative Stress in Metabolic Syndrome. Int. J. Mol. Sci. 2023;24(9):7898. DOI: 10.3390/ijms24097898

26. Poletto A.C., David-Silva A., Yamamoto A.P. d.M., Machado U.F., Furuya D.T. Reduced Slc2a4/GLUT4 expression in subcutaneous adipose tissue of monosodium glutamate obese mice is recovered after atorvastatin treatment. Diabetol. Metab. Syndr. 2015;7:18. DOI: 10.1186/s13098-015-0015-6

27. Venditti P., Stefano L., Meo S. Mitochondrial metabolism of reactive oxygen species. Mitochondrion. 2013;13(2):71—82. DOI: 10.1016/j.mito.2013.01.008

28. Gruzdeva O.V., Borodkina D.A., Akbasheva O.E., Dyleva Yu.A., Antonova L.V., Matveeva V.G., Ivanov S.V. et al. Adipocine-cytokine profile of adipocytes epicardial adipose tissue with coronary heart disease on the background of visceral obesity. Obesity and metabolism. 2017;14(4):38–45. (In Russian). DOI: 10.14341/OMET2017438-45

29. Deeva T.A. Clinical significance of noninvasive fibrosis markers in patients with metabolic syndrome: dis. сand. med. sciences. Moscow. 2015:145. (In Russian). [Electronic resource]. URL: https://www.sechenov.ru/upload/medialibrary/c72/dissertatsiya_deeva_03.12.15_ispravlen_.pdf

30. Vavilova T.P., Pleten’ A.P., Mikheev R.K. Biological role of adipokines and their association with morbid conditions. Voprosy pitaniia [Problems of Nutrition]. 2017;86(2):5–13. (In Russian).

31. Wu Z.J., Cheng Y.J., Gu W.J., Aung H.L. Adiponectin is associated with increased mortality in patients with already established cardiovascular disease: A systematic review and metaanalysis. Metabolism. 2014;63(9):1157–66. DOI: 10.1016/j.metabol.2014.05.001

32. Shibata R., Ouchi N., Takahashi R., Terakura Y., Ohashi K., Ikeda N. et al. Omentin as a novel biomarker of metabolic risk factors. Diabetol. Metab. Syndr. 2012;4(1):37. DOI: 10.1186/1758-5996-4-37

33. Alpert M.A, Omran J., Bostick B.P. Effects of obesity on cardiovascular hemodynamics, cardiac morphology, and ventricular function. Curr. Obes. Rep. 2016;5(4):424–34. DOI: 10.1007/s13679-016-0235-6

34. Bubnova M.G. The role of obesity and visceral heart fat in triggering the cardiovascular continuum. Clinical effects of orlistat. Regular issues of “RMJ”. 2014;2:116–124. (In Russian).

35. Azimova M.O., Blinova N.V., Zhernakova Yu.V., Chazova I.E. Obesity as a predictor for disease development: role of localized fat depot. Systemic hypertension. 2018;15(3):39–43. (In Russian). DOI: 10.26442/2075-082X_2018.3.39-43

36. Dela Cruz C.S., Matthay, R.A. Role of obesity in cardiomyopathy and pulmonary hypertensio. Clinics in Chest Medicine. 2009;30(3):509– 523. DOI: 10.1016/j.ccm.2009.06.001

37. Park J-S., Lee Y-H., Seo K-W., Choi B-J., Choi S-Y., Yoon M-H. et al. Echocardiographic epicardial fat thickness is a predictor for target vessel revascularization in patients with ST-elevation myocardial infarction. Lipids in Health and Disease. 2016;15(1):194. DOI: 10.1186/s12944-016-0371-8

38. Britton K.A, Pedley A., Massaro J.M, Corsini E.M., Murabito J.M., Hoffmann U., Fox C.S. Prevalence, Distribution, and Risk Factor Correlates of High Thoracic Periaortic Fat in the Framingham Heart Study. Journal of the American Heart Association. 2012;1(6):e004200. DOI: 10.1161/JAHA.112.004200

39. Martinelli I., Tomassoni D., Moruzzi M., Roy P., Cifani C., Amenta F., Tayebati S.K. Cardiovascular Changes Related to Metabolic Syndrome: Evidence in Obese Zucker Rats. Int. J. Mol. Sci. 2020;21(6):2035. DOI: 10.3390/ijms21062035

40. Romantsova T.I., Ovsyannikovna A.V. Perivascular adipose tissue: role in the pathogenesis of obesity, type 2 diabetes mellitus and cardiovascular pathology. Obesity and metabolism. 2015;12(4):5–13. (In Russian). DOI: 10.14341/omet201545-13

41. Gritsenko O.V., Chumakova G.A., Elchaninova S.A. et al. Lipotoxicity damage of myocardium in obesity. Cardiosomatics. 2017;8(4):36–40. (In Russian). DOI: 10.26442/CS45386

42. Wang J., Xiang Bo, Hung-Yu Lin, Freed D., Arora R.C., Tian G.. Pathological mechanism for delayed hyperenhancement of chronic scarred myocardium in contrast agent enhanced magnetic resonance imaging. PloS One. 2014;9(5):e96463. DOI: 10.1371/journal.pone.0096463

43. Yazyeva D.S., Fedotova D.A. Morphohistological changes of the myocardium in obesity. Bulletin of Medical Internet conferences. 2017;7(1).(In Russian). [Electronic resource]. URL: www.medconfer.com 265. ID: 2017-01-6-T-10658.

44. López B., González A., Ravassa S., Beaumont J., Moreno M.U., San José G., Querejeta R., Díez J. Circulating biomarkers of myocardial fibrosis. J. Am. Coll. Cardiol. 2015;65(22):2449–2456. DOI: 10.1016/j.jacc.2015.04.026

45. Morelli M., Gaggini M., Daniele G., Marraccini P., Sicari R., Gastaldelli A. Ectopic fat: the true culprit linking obesity and cardiovascular disease? Thromb. Haemost. 2013;110(4):651–60. DOI: 10.1160/TH13-04-0285

46. Gioeva Z.M., Bogdanov A.R., Zaletova T.S., Bogdanova A.A. Obesity as a Risk Factor for Chronic Heart Failure: a Review of the Literature. Doctor.Ru. 2017;10(139):21–25. (In Russian).

47. Logacheva I.V., Ryazanova T.A., Makarova V.R., Avzalova F.R., Maksimov N.I. Heart remodeling in overweight and odesity with cardiac comorbidities. Russ. J. Cardiol. 2017;(4):40–46. (In Russian). DOI: 15829/1560-4071-2017-4-40-46

48. Vecchié A., Dallegri F., Carbone F., Bonaventura A., Liberale L., Portincasa P., Gema Frühbeck G., Montecucco F. Obesity phenotypes and their paradoxical association with cardiovascular diseases. Eur. J. Intern. Med. 2018.48:6–17. DOI: 10.1016/j.ejim.2017.10.020

49. Chumakova G.A., Veselovskaya N.G. Clinical significance of visceral obesity. M. GEOTAR-Media. 2016:160. (In Russian)].

50. Dudenbostel T., Ghazi L., Liu M., Li P., Oparil S, Calhoun D.A. Body mass index predicts 24-hour urinary aldosterone levels in patients with resistant hypertension. Hypertension. 2016;68(4):995–1003. DOI: 10.1161/HYPERTENSIONAHA.116.07806

51. Pilitsi E.E., O.M. Farr J.M., Polyzos S.A., Perakakis N, Nolen-Doerr E., Papathanasiou A.E., Mantzoros C.S. Pharmacotherapy of obesity: available medications and drugs under investigation. Metabolism. 2018;31:S0026–0495(18)30228–2. DOI: 10.1016/j.metabol.2018.10.010

52. Heinzel F.R., Hohendanner F., Jin G., Sedej S., Edelmann F. Myocardial hypertrophy and its role in heart failure with preserved ejection fraction. J. Appl. Physiol .2015;119(10):1233–42. DOI: 10.1152/japplphysiol.00374.2015

53. Gritsenko O.V., Chumakova G.A., Shevlyakov I.V., Trubina E.V. The mechanisms of heart failure development in obesity. Russian journal of cardiology. 2018;23(5):81–86. (In Russian). DOI: 10.15829/1560-4071-2018-5-81-86

54. Matloch Z., Kotulák T., Haluzík M. The role of epicardial adipose tissue in heart disease. Physiol. Res.2016;65(1):23–32. DOI: 10.33549/physiolres.933036

55. Druzhilov M.A., Beteleva Yu.E., Druzhilo va O.Yu., Andreeva E.S., Kuznetsova T.Yu. The role of epicardial obesity in the development of structural and functional remodeling of the heart. Russian journal of cardiology. 2017;(4):35–39. (In Russian). DOI: 10.15829/1560-4071-2017-4-35-39

56. Travers J.G., Kamal F.A., Robbins J. et al. Cardiac Fibrosis: The Fibroblast Awakens. Circ. Res. 2016;118(6):1021–40. DOI: 10.1161/CIRCRESAHA.115.306565.

57. Finicelli M., Squillaro T., Di Cristo F., Di Salle A., Melone M.A.B., Galderisi U., Peluso G. Metabolic syndrome, Mediterranean diet, and polyphenols: Evidence and perspectives. J. Cell. Physiol. 2019;234(5):5807–5826. DOI: 10.1002/jcp.27506.

58. López B., González A., Ravassa S., Beaumont J., Moreno M. U., San José G., Querejeta R., Díez J. Circulating biomarkers of myocardial fibrosis. J. Am. Coll. Cardiol. 2015;65(22):2449–2456. DOI: 10.1016/j.jacc.2015.04.026

59. Rudenko T.E., Kamyshova E.S., Vasilyeva M.P., Bobkova I.N., Solomatina N.I., Shvetsova M.Yu. Risk factors for diastolic left ventricular myocardial dysfunction in patients with chronic kidney disease. Therapeutic archive. 2018;09:60–67. (In Russian). DOI: 10.26442/terarkh201890960-67

60. Martynenko T.I., Paraeva O.S., Dronov S.V., Shoikhet Ya.N. New approaches to primary differentiation of dyspnea in patient with pulmonary and cardiac pathology. Clinical medicine (Russian journal). 2014;92(9):45–51. (In Russian). УДК 616.24-008.47-079.4

61. Poddar M., Chetty Y., Chetty V.T. How does obesity affect the endocrine system? A narrative review. Clin. Obes. 2017;7(3):136–44. DOI: 10.1111/cob.12184

62. McQuillan C., Gray A., Kearney A, Menown I.B.A. Advances in clinical cardiology 2017: a summary of key clinical trials. Advances in Therapy. 2018;35(7):899–927. DOI: 10.1007/s12325-018-0716-y

63. Pathak R.K., Mahajan R., Lau D.H. et al. The implications of obesity for cardiac arrhythmia mechanisms and management. Canadian Journal of Cardiology. 2015;31(2):203–210. DOI: 10.1016/j.cjca.2014.10.027

64. Praskurnichiy E.A., Morozova O.I. Clinical and Pathogenetic Assessment of Relationships Between the Dynamics of Body Weight Changes and Atrial Fibrillation in Patients with Primary Obesity. The Russian archives of internal medicine. 2021;11(5):389–400. (In Russian). DOI: 10.20514/2226-6704-2021-11-5-389-400

65. Nalliah C.J., Sanders P., Kottkamp H., Kalman J.M. The role of obesity in atrial fibrillation. European Heart Journal. 2016;37(20):1565–72. DOI:10.1093/eurheartj/ehv486.

66. Huang H., Amin M., Gurin E., Wan E., Thorp S., Homma J.P. Dietinduced obesity causes long QT and reduces transcription of voltagegated potassium channels. J. Mol. Cell. Cardiol. 2013;59:151–158. DOI: 10.1016/j.yjmcc.2013.03.007

67. Kovesdy C.P., Furth S.L., Zoccali C. World Kidney Day Steering Committee. Obesity and kidney disease: hidden consequences of the epidemic. Blood Purif. 2017;43(4):346–54. DOI: 10.1159/000458481

68. Mareev V.Yu., Ageev F.T., Arutyunov G.P., Koroteev A.V., Ovchinnikov A.G., Belenkov Yu.N. et al. National guidelines for the diagnosis and treatment of CHF (fourth revision). Heart failure. 2013; 14(7):379–472. (In Russian). УДК 616.12–008.46–036.12 (083.13)

69. Miklishanskaya S.V., Solomasova L.V., Mazur M.A. Obesity and Mechanisms of its Negative Impact on the Cardiovascular System. Rational pharmacotherapy in cardiology. 2020;16(1):108–117. (In Russian). DOI: 10.20996/1819-6446-2020-02-09

70. Alpert M. A., Omran J., Mehra A., Ardhanari S. Impact of obesity and weight loss on cardiac performance and morphology in adults. Progress in Cardiovascular Diseases. 2014;56(4):391–400. DOI: 10.1016/j.pcad.2013.09.003

71. Gavryushina S.V., Ageev F. T. Heart failure with preserved left ventricular ejection fraction: epidemiology, patient «portrait», clinic and diagnostics. Cardiology. 2018;58(S4):55–64. (In Russian). DOI: 10.18087/cardio.2467

72. Ivanov S.I., Alekhin M.N. Myocardial work in assessment of left ventricular systolic function. Cardiologiia. 2020;60(3):80–88. (In Russian). DOI: 10.18087/cardio.2020.3.n925

73. Ponomarenko I.V., Sukmanova I.A., Sanaeva A.K., Trubina E.V., Narenkova S.O. The possibilities of speckle-tracking echocardiography in the diagnosis of subclinical left ventricular dysfunction. Cardiology: news, opinions, training. 2023;11(2):22–29. (In Russian). DOI: 10.33029/2309-1908-2023-11-2-22-29

74. Doğduş M., Kılıç S., Vuruşkan E. Evaluation of subclinical left ventricular dysfunction in overweight people with 3D speckle tracking echocardiography. Anatol. J. Cardiol 2019;21(4):180–6. DOI: 10.14744/AnatolJCardiol.2018.40456

75. Gritsenko O.V., Chumakova G.A., Trubina E.V. Features of speckle tracking echocardiography for diagnosis of myocardial dysfunction. Cardiosomatics. 2021;12(1):5–10. (In Russian). DOI: 10.26442/22217185.2021.1.200756

76. Tsyplenkova N.S., Panova E.I. Heart rate features among men of working age with obesity and hypertension. Obesity and metabolism. 2016;13(1):30–35. (In Russian). DOI: 10.14341/omet2016130-35

77. Solov’yeva A.V., Cherdantseva T.M., Cheskidov A.V., Shukis K.A. Clinical and Morphological Features of Lipomatous Hypertrophy of Interatrial Septum in Patients with Diseases of Cardiovascular System. Science of the young (Eruditio Juvenium). 2022;10(2):157–164. (In Russian). DOI: 10.23888/HMJ2022102157-164

78. Van Veldhuisen, D.J., Linssen G.C., Jaarsma T., van Gilst W.H., Hoes A.W., Tijssen J.G., et al. B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction. J. Am. Coll. Cardiol. 2013;61(14):1498–506. DOI: 10.1016/j.jacc.2012.12.044

79. Mauad F., Chagas-Neto F., Benedeti A. et al. Reproducibility of abdominal fat assessment by ultrasound and computed tomography. Radiol. Bras. 2017;50(3):141–7. DOI:10.1590/0100-3984.2016.0023

80. Shlyahto E.V., Nedogoda S.V., Conrady A.O. et al. Diagnosis, treatment, and prevention of obesity and related diseases (national clinical guidelines). Saint Petersburg. 2017:164. (In Russian).

81. Kuznetsova T.Yu., Chumakova G.A., Druzhilov M.A., Veselovskaya N.G. Clinical application of quantitative echocardiographic assessment fat tissue in obesity. Russian Journal of Cardiology. 2017;(4):81–87. (In Russian). DOI: 10.15829/1560-4071-2017-4-81-87

82. Zhangt T., Q. Xue Q., Zhu R., Jiang Y. Diagnostic Value of PICP and PIIINP in Myocardial Fibrosis: A Systematic Review and Metaanalysis. Clin. Cardiol. 2022 Dec 5. DOI: 10.1002/clc.23901

83. Drapkina O.M., Zyatenkova T.V. Markers of fibrosis in patients with metabolic syndrome. Russian Medical Journal. 2016.26:1727–1731. (In Russian).

84. Castro A.I., Gomez-Arbelaez D., Crujeiras A.B., Granero R., Aguera Z., Jimenez-Murcia S. et al. Effect of A Very Low-Calorie Ketogenic Diet on Food and Alcohol Cravings, Physical and Sexual Activity, Sleep Disturbances, and Quality of Life in Obese Patients. Nutrients. 2018;21;10(10):E1348. DOI: 10.3390/nu10101348

85. Millard H.R., Musani S.K., Dibaba D.T., Talegawkar S.A., Taylor H.A.,Tucker K.L., Bidulescu A. Dietary choline and betaine; associations with subclinical markers of cardiovascular disease risk and incidence of CVD, coronary heart disease and stroke: the Jackson Heart Study. Eur. J. Nutr. 2018;57(1):51–60. DOI: 10.1007/s00394-016-1296-8

86. Hanafy A.S., Elkatawy H.A. Beneficial effects of vitamin D on insulin sensitivity, blood pressure, abdominal subcutaneous fat thickness, and weight loss in refractory obesity. Clin Diabetes. 2018;36(3):217–225. DOI: 10.2337/cd17-0099

87. Skvortsov V.V., Malyakina E.A., Malyakin G.I. An addition to pharmacological correction of carbohydrate and lipid metabolism in patients with metabolic syndrome. Lechaschi Vrach. 2022;12(25):44–50. (In Russian). DOI: 10.51793/OS.2022.25.12.008

88. Huwiler V.V., Schönenberger K.A., Segesser von Brunegg A. et al. Prolonged Isolated Soluble Dietary Fibre Supplementation in Overweight and Obese Patients: A Systematic Review with Meta-Analysis of Randomised Controlled Trials. Nutrients. 2022;14(13):2627. DOI: 10.3390/nu14132627

89. Kränkel N., Bahls M., Van Craenenbroeck E.M., Adams V., Serratosa L., Solberg E.E., D.D. Hansen D.D., Dörr M., Kemps H. Exercise training to reduce cardiovascular risk in patients with metabolic syndrome and type 2 diabetes mellitus: How does it work? Eur. J. Prev. Cardiol. 2019;26(7):701–708. DOI: 10.1177/2047487318805158

90. Hruby A., Sahni S., Bolster D., Jacques P.F. Protein intake and functional integrity in aging: the Framingham Heart Study Offspring. J. Gerontol. A Biol. Sci. med. Sci. 2020;75(1):123–130. DOI: 10.1093/gerona/gly201

91. Kashtanova D.A., Tkacheva J.N., Doudinskaya E.N., Strazhesko I.D., Kotovskaya Y.V., Popenko A.S., Tyakht A.V., Alexeev D.R. Gut microbiota in patients with different metabolic statuses: Moscow Study. Microorganisms. 2018;6(4):E98. DOI: 10.3390/microorganisms6040098.

92. Kobyliak N., Falalyeyeva T., Boyko N., Tsyryuk O., Beregova T., Ostapchenko L. Probiotics and nutraceuticals as a new frontier in obesity prevention and management. Diabetes Res Clin. Pract. 2018;141:190–199. DOI: 10.1016/j.diabres.2018.05.005

93. Hayes J.F, Bhaskaran K., Batterham R., Smeeth L., Douglas I. The effect of sibutramine prescribing in routine clinical practice on cardiovascular outcomes: a cohort study in the United Kingdom. International Journal of Obesity. 2015;39(9);1359–64. DOI: 10.1038/ijo.2015.86

94. Khera R., Murad M.H., Chandar A.K., Dulai P.S., Wang Z, Prokop J., Loomba R., Camilleri M., Singh S. Association of Pharmacological Treatments for Obesity with Weight Loss and Adverse Events: A Systematic Review and Meta-analysis. JAMA. 2016; Jun 14; 315(22):2424–34. DOI: 10.1001/jama.2016.7602

95. McQuillan C., Gray A., Kearney A., Menown I.B.A. Advances in Clinical Cardiology 2017: A Summary of Key Clinical Trials. Advances in Therapy. 2018;35(7):899–927. DOI: 10.1007/s12325-018-0716-y.

96. Bohula E.A., Scirica S.E., Inzucchi D.K. et al. Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial. Lancet. 2018;392(10161):2269–2279. DOI: 10.1016/S0140-6736(18)32328-6

97. Alfaris N., Minnick A.M., Hopkins C.M., Berkowitz R.I., Wadden T.A. Combination phentermine and topiramate extended release in the management of obesity. Expert. Opin Pharmacother. 2015;16(8):1263–74. DOI: 10.1517/14656566.2015.1041505

98. Sudakin D. Naltrexone: Not Just for Opioids Anymore. J. Med. Toxicol. 2016;12(1):71–5. DOI: 10.1007/s13181-015-0512-x

99. Sundström J., Bruze G., Ottosson J., Marcus C., Näslund I., Neovius M. Weight loss and heart failure. A Nationwide Study of Gastric Bypass Surgery Versus Intensive Lifestyle Treatment. Circulation. 2017;135(17):1577–1585. DOI: 10.1161/CIRCULATIONAHA.116.025629

100. Troshina E.A., Ershova E.V., Mazurina N.V. Endocrinological aspects of bariatric surgery. Consilium Medicum. 2019;21(4):50–55. (In Russian). DOI: 10.26442/20751753.2019.4.190336

101. Dedov I.I., Mel’nichenko G.A., Shestakova M.V., Troshina E.A., Mazurina N.V., Shestakova E.A., Yashkov Yu.I., Neimark A.E. et al. Russian national clinical recommendations for morbid obesity treatment in adults. 3rd revision (Morbid obesity treatment in adults). Obesity and metabolism. 2018;15(1):53–70. (In Russian). DOI: 10.14341/omet2018153-70

102. Greenblatt H.K., Greenblatt D.J. Meldonium (Mildronate): A Performance-Enhancing Drug? Clin. Pharmacol. Drug Dev.2016.5(3):167–9. DOI: 10.1002/cpdd.264

103. Zhong Y., Zhong P., He S., Zhang Y., Tang L., Ling Y., Fu S. et al. Trimetazidine protects cardiomyocytes against hypoxia/ reoxygenation injury by promoting AMP-activated protein kinase-dependent autophagic flux. J. Cardiovasc. Pharmacol. 2017;69(6):389–397. DOI: 10.1097/FJC.0000000000000487